Miles Wang, an OpenAI researcher known for using AI to accelerate scientific discovery, is leaving the company to launch an AI drug discovery startup. The venture is in talks to raise $200 million at a $2 billion valuation, according to sources cited by TechCrunch's Marina Temkin.
A $2B bet on AI-driven pharma
The valuation is eye-popping for a pre-launch company. It underscores the massive capital inflows into AI, even as the broader crypto market sits in extreme fear. Wang's work at OpenAI focused on applying AI to biological problems — a niche that's suddenly very hot. Drug discovery is expensive and slow; AI promises to cut both. Investors are betting big that Wang can deliver.
📊 Market Data Snapshot
Why this isn't a crypto story — yet
Here's the catch: the $200 million is all traditional venture capital. No token sale, no on-chain component. That's a reality check for the decentralized science (DeSci) crowd. The best AI talent still prefers equity over tokens, especially in a bear market. Projects like VitaDAO or Molecule have yet to attract this caliber of researcher or this size of check. For crypto-native AI tokens — FET, AGIX, OCEAN — the news is a mixed signal. It validates the AI-in-biotech thesis, but it also shows where the real money flows.
Market context: extreme fear, muted reaction
The timing isn't great. The Fear & Greed Index sits at 25 — extreme fear. Bitcoin is at $64,540, with high dominance and altcoins underperforming. Any pump in AI tokens from this headline will likely be shallow and short-lived. Traders chasing a 3-5% spike risk getting caught when volume fades. The broader market is too risk-off to sustain a narrative-driven rally.
Wang's startup hasn't announced any plans to use blockchain or issue a token. If it later adopts crypto for data provenance or IP tokenization, that could catalyze a DeSci narrative. But for now, the $200 million is earmarked for equity, not tokens. Whether that changes will determine if this story becomes a crypto catalyst or a cautionary tale.
